Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in ...
Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates ...
MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...
Adding camrelizumab and rivoceranib to TACE improved PFS in patients with unresectable HCC in a phase 2 trial.
FLC is a rare liver cancer with unique genetic traits, often misdiagnosed until advanced. New research and a clinical trial ...
(RTTNews) - Coherus BioSciences, Inc. (CHRS), Wednesday announced final data from its Phase 2 study evaluating casdozokitug in combination with atezolizumab and bevacizumab in patients with ...
Announcing a new publication for Acta Materia Medica journal. Epithelial cell adhesion molecule (EpCAM) is a biomarker for epithelial cell-derived tumors.
Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor ...
With better risk stratification, clinicians may be able to optimize medical management of patients with chronic HBV who don’t ...
The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...
Cellular senescence, where cells permanently stop dividing, plays a complex role in liver health. In a recent review article, ...
Casdozokitug has been granted Orphan Drug designation and Fast Track designation for the treatment of refractory hepatocellular carcinoma from the FDA. It is the first IL-27 antibody to enter the ...